Development
GSK plc
GSK
$41.30
$0.441.08%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 434.76M | 1.85B | 2.03B | 1.81B | 1.76B |
| Total Depreciation and Amortization | 773.87M | 733.09M | 565.78M | 777.13M | -169.13M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 626.06M | -112.69M | -101.39M | 82.57M | 1.98B |
| Change in Net Operating Assets | 2.14B | 326.66M | -861.19M | -2.60B | -1.33B |
| Cash from Operations | 3.97B | 2.80B | 1.64B | 64.36M | 2.24B |
| Capital Expenditure | -603.70M | -378.57M | -370.51M | -282.93M | -514.43M |
| Sale of Property, Plant, and Equipment | 8.70M | 13.93M | 3.76M | 8.50M | 156.21M |
| Cash Acquisitions | -2.48M | -79.77M | -1.75B | -1.21M | -97.48M |
| Divestitures | -8.70M | -2.53M | 80.11M | -7.29M | -28.19M |
| Other Investing Activities | 939.08M | -174.73M | 834.90M | -212.50M | -150.34M |
| Cash from Investing | 332.90M | -621.67M | -1.21B | -495.42M | -634.23M |
| Total Debt Issued | -1.41B | -615.00M | 1.70B | 552.00M | 1.23B |
| Total Debt Repaid | -1.41B | -483.00M | -706.00M | -191.00M | -1.69B |
| Issuance of Common Stock | 1.00M | 0.00 | 3.00M | 8.00M | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -2.00M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -705.55M | -717.89M | -697.21M | -673.92M | -768.12M |
| Other Financing Activities | -206.00M | -97.00M | -404.00M | -130.00M | -225.00M |
| Cash from Financing | -4.46B | -2.23B | 38.80M | -386.14M | -1.57B |
| Foreign Exchange rate Adjustments | -42.23M | 29.12M | -71.35M | -37.64M | 54.03M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -201.23M | -22.79M | 396.80M | -854.85M | 85.74M |